22 Nov 14:06
by Kenichiro Ito,
Yoshihiko Matsuda,
Ayako Mine,
Kyohei Miyairi,
Yoshimi Kikuchi,
Atsushi Konishi
A heterodimeric macrocyclic peptide inhibitor against VEGF-VEGFR2 interaction was designed and produced by a microbial secretion system. It showed stronger binding potency and >1000 higher inhibitory activity against VEGFR2 than parental monomeric macrocyclic peptides.
Abstract
The inhibition of protein-protein interactions (PPIs) is an effective approach for therapy. Owing to their large binding surface areas to target proteins, macrocyclic peptides are suitable molecules for PPI inhibition. In this study, we developed single-chain tandem macrocyclic peptides (STaMPtides) that inhibits the vascular endothelial growth factor (VEGF) receptor 2 (VEGFR2). They were artificially designed to comprise two different VEGFR2-binding macrocyclic peptides linked in tandem by peptide linkers and secreted by Corynebacterium glutamicum. Most potent VEGFR2-inhibitory STaMPtides with length-optimized linkers exhibited >1000 times stronger inhibitory activity than their parental monomeric peptides, possibly due to the avidity effect of heterodimerization. Our approach of using STaMPtides for PPI inhibition may be used to inhibit other extracellular factors, such as growth factors and cytokines.
21 Nov 21:31
by Damian L. Stachura, Stephanie Nguyen, Steven W. Polyak, Blagojce Jovcevski, John B. Bruning, and Andrew D. Abell

ACS Infectious Diseases
DOI: 10.1021/acsinfecdis.2c00452
08 Nov 13:22
by Cornelis J. Slingerland, Ioli Kotsogianni, Charlotte M. J. Wesseling, and Nathaniel I. Martin

ACS Infectious Diseases
DOI: 10.1021/acsinfecdis.2c00307
03 Nov 18:45
Researchers have used a combination of genetic manipulation and protein structural analysis to determine how the position of 'bulky' amino acids influences the ability of efflux pump inhibitors to bind bacterial pump proteins and so reduce their resistance to antibiotics. This work has implications for our understanding of bacterial antibiotic resistance, and may be useful in the rational design of drugs that target bacteria that have evolved antibiotic resistance.
03 Nov 18:45
by Vinayak Singh, Anna E. Grzegorzewicz, Stephen Fienberg, Rudolf Müller, Lutete Peguy Khonde, Olalla Sanz, Salvatore Alfonso, Beatriz Urones, Gerard Drewes, Marcus Bantscheff, Sonja Ghidelli-Disse, Thomas R. Ioerger, Bhanupriya Angala, Jiuyu Liug, Richard E. Leeg, James C. Sacchettinih, Inna V. Kriegerh, Mary Jackson, Kelly Chibale, and Sandeep R. Ghorpade

ACS Infectious Diseases
DOI: 10.1021/acsinfecdis.2c00392
02 Nov 13:36
Physicists have identified a natural delivery system which can safely carry potent antibiotics throughout the body to selectively attack and kill bacteria by using red blood cells as a vehicle.
02 Nov 13:36
by Nikhil Aggarwal, Shohei Kitano, Ginette Ru Ying Puah, Sandra Kittelmann, In Young Hwang, and Matthew Wook Chang

Chemical Reviews
DOI: 10.1021/acs.chemrev.2c00431
26 Oct 12:57
by Christian Avalos-Gómez
Curr Pharm Des. 2022 Oct 25. doi: 10.2174/1381612829666221025153216. Online ahead of print.
ABSTRACT
The emergence of multidrug-resistant bacterial strains with respect to commercially available antimicrobial drugs has marked a watershed in treatment therapies to fight pathogens and has stimulated research on alternative remedies. Proteins of the innate immune system of mammals have been highlighted as potentially yielding possible treatment options for infections. Lactoferrin (Lf) is one of these proteins; interestingly, no resistance to it has been found. Lf is a conserved cationic nonheme glycoprotein that is abundant in milk and is also present in low quantities in mucosal secretions. Moreover, Lf is produced and secreted by the secondary granules of neutrophils at infection sites. Lf is a molecule of approximately 80 kDa that displays multiple functions, such as antimicrobial, anti-viral, anti-inflammatory, and anticancer actions. Lf can synergize with antibiotics, increasing its potency against bacteria. Lactoferricins (Lfcins) are peptides resulting from the N-terminal end of Lf by proteolytic cleavage with pepsin. They exhibit several anti-bacterial effects similar to those of the parental glycoprotein. Synthetic analog peptides exhibiting potent antimicrobial properties have been designed. The aim of this review is to update understanding of the structure and effects of Lf and Lfcins as anti-bacterial compounds, focusing on the mechanisms of action in bacteria and the use of Lf in treatment of infections in patients, including those studies where no significant differences were found. Lf could be an excellent option for prevention and treatment of bacterial diseases, mainly in combined therapies with antibiotics or other antimicrobials.
PMID:36284379 | DOI:10.2174/1381612829666221025153216